Cigarette smoking increases the risk of serious cardiovascular side effects from oral-contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies,15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
(LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS)
21 light-orange Nordette tablets, each containing 0.15 mg of levonorgestrel, (d (-)-13 beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one), a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol, (19-nor-17α-pregna-1,3,5 (10)-trien-20-yne-3,17-diol), and 7 pink inert tablets.
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and the IUD, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
Media Articles Related to Nordette (Levonorgestrel / Estradiol)
LARC versus SARC: Major study demonstrates clear benefits of long-acting reversible contraception compared to short-acting reversible contraception
Source: Sexual Health / STDs News From Medical News Today [2016.09.22]
Benefits of increased voluntary uptake of LARC may extend to wider populations than previously thought, according to a major study in the American Journal of Obstetrics and Gynecology.
Published Studies Related to Nordette (Levonorgestrel / Estradiol)
Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. [2011.08]
BACKGROUND: Cytochrome P450 3 A is involved in ticagrelor and ethinyl oestradiol/levonorgestrel metabolism; so a potential drug-drug interaction may occur. OBJECTIVES: To assess: ticagrelor effects on ethinyl oestradiol/levonorgestrel pharmacokinetics, endogenous sex hormone levels; ethinyl oestradiol/levonorgestrel effects on ticagrelor pharmacokinetics; tolerability of ticagrelor + ethinyl oestradiol/levonorgestrel... CONCLUSIONS: Ticagrelor co-administration with ethinyl oestradiol/levonorgestrel increased ethinyl oestradiol exposure by approximately 20%, with no effect on levonorgestrel pharmacokinetics. No clinically relevant effect on contraceptive efficacy is expected with ethinyl oestradiol/levonorgestrel and ticagrelor co-administration.
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. [2006.07]
OBJECTIVE: This study aimed to compare the effects on hemostasis variables of a contraceptive vaginal ring with those of an oral contraceptive... CONCLUSION: The contraceptive vaginal ring affected some measured hemostasis variables and sex hormone-binding globulin differently from the oral contraceptive, most likely because of difference in androgenicity of the progestins. The results suggest that the contraindications for oral contraceptive use would also apply to the tested contraceptive vaginal ring.
Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers. [2001.12]
In the present study the effect on the urinary excretion of vasoactive markers of two oral contraceptives (OCs), i.e., Leios, containing 0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel, and Stediril 30, containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, was investigated... Levonorgestrel may elicit no impact on these estrogen-induced changes that, however, seem only to be manifested after a longer treatment period.
A prospective randomized study comparing the clinical effects of a norethisterone and a levonorgestrel containing low dose oestrogen oral contraceptive pills. [1993.02]
The two types of low dose oral contraceptives one containing levonorgestrel the other containing norethisterone have been compared in a randomized prospective study. We have found that cycle control was much poorer with the norethisterone pill and would therefore recommend that if the norethisterone-containing pill needs to be prescribed then either the 1 mg or the 'synphasic' preparation should be considered..
A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study. [1993.01]
Menstrual bleeding patterns were investigated in young women taking either a levonorgestrel triphasic, Triquilar, or a norethindrone triphasic, Ortho 7/7/7, two commonly prescribed low-dose oral contraceptives. The levonorgestrel triphasic contains ethinyl estradiol (EE) 30 micrograms + levonorgestrel (LNG) 50 micrograms for the first six days, EE 40 micrograms + LNG 75 micrograms for the following five days, and EE 30 micrograms + LNG 125 micrograms for the last ten days...
Clinical Trials Related to Nordette (Levonorgestrel / Estradiol)
AZD6140 Oral Contraceptive Interaction Study [Completed]
A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale [Completed]
This is a 4-arm study to evaluate and compare bleeding patterns between three different
doses of DR-1031 oral contraceptive with Seasonale oral contraceptive. Study participants
will receive physical and gynecological exams, including Pap smear. During the study, all
participants will be required to complete a diary
Evaluation Of The Product Ciclo® 21 Pharmacodynamics (Levonorgestrel + Ethinyl Estradiol), Marketed By UniÃ£o QuÃmica FarmacÃªutica Nacional S / A, Compared To Nordette® Product To The Lab Wyeth Pharmaceutical Industries Ltd. [Not yet recruiting]
Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química
Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical
Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by
measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation
demonstrated by transvaginal ultrasound examinations
Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects [Completed]
This open-label, fixed-sequence crossover study aims to evaluate the effect of GSK1265744
(744) oral administration on the pharmacokinetics (PK) and pharmacodynamics (PD) of a
commonly used oral contraceptive (OC) product (combination of ethinyl estradiol and
levonorgestrel), in 20 healthy female subjects. Each subject will participate in a Run-in
Period (if needed), followed by a single-sequence Treatment Period. Subjects will receive
oral contraceptive containing Levonorgestrel and Ethinyl Estradiol on Days 1 to 21 and be OC
free on Days 22 to 28, during which withdrawal menses should occur. Subjects will receive OC
alone on Days 1 to 10. Levonorgestrel (LNG) and ethinyl estradiol (EE) PK will be determined
on Day 10. Subjects will then co-administer 744 and OC on Days 11 to 21. Levonorgestrel
and ethinyl estradiol PK will be determined again on Day 21 to assess if co-administration
with 744 results in a significant change in OC exposure compared to OC alone. Subjects will
return to the study center for final follow-up evaluations 7 to 14 days after the last dose
of study medication (Days 28 to 35).
Quartet Lead and Resynchronization Therapy Options [Completed]
The purpose of this Clinical Trial is to determine the percentage of patients whose
hemodynamic response improves with the different configurations offered by the new Quartet®
left ventricular lead, as a result of its four electrodes, with respect to the
configurations offered by a standard bipolar lead.
Furthermore, the optimal stimulation configuration will be determined from a comparison with
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Nordette has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Nordette review by 46 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || pregnancy avoidance|
|Dosage & duration:|| || 1 pill taken daily for the period of 8 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || pregnancy avoidance, worked perfectly, did not get pregnant until stopped taking the meidaction, then 3 months later conceived|
|Side effects:|| || none - no apparent side effects whatsoever. periods were normal when on inert pills. Periods came like clockwork|
|Comments:|| || basic - took nordette before and after bearing children. switched to mirena iud after child bearing years|
Page last updated: 2016-09-22